Update: Präklinische Entwicklungen zur Therapie der pulmonalen arteriellen Hypertonie

Zusammenfassung

Die pulmonale arterielle Hypertonie (PAH) wird derzeit mit Substanzen behandelt, die primär eine Wiederherstellung der Balance des pulmonalvaskulären Tonus bewirken – namentlich die Prostanoide, Antagonisten des Endothelinrezeptors und die PDE-5-Inhibitoren – auch wenn diese Substanzen auch antiproliferative Effekte besitzen. Andere Substanzen, die direkt das Remodeling der Pulmonalarterien adressieren, werden derzeit nicht nur in präklinischen Tiermodellen, sondern auch bereits in klinischen Studien untersucht. Der Fokus der Grundlagenforschung liegt dabei sowohl auf der Ebene von Mediatoren und Rezeptoren, auf der Ebene von intrazellulären Signaltransduktionswegen und Transkriptionsfaktoren, sowie auf der Ebene der Effektoren.

Summary

Pulmonary arterial hypertension is a life-threatening, vasculoproliferative disease of the lung, which is characterized by vasoconstriction and remodeling of small pulmonary arteries. Drugs for the treatment of PAH mainly address the increased vascular tone. Substances like prostacyclin, endothelin-receptor-antagonists and phosphodiesterase-5-inhibitors have been approved for the treatment of PAH and represent the current therapeutic options. The development of a causal treatment aiming a normalization of the vessel wall structure is the current focus of research. The key events in disease progression are represented by increased proliferation, migration and a resistance to apoptosis of pulmonary vascular cells. Therefore, new non-vasoactive drugs are investigated in relevant preclinical animal models of pulmonary arterial hypertension. Some of these substances, like tyrosine kinase inhibitors, elastase inhibitors and phosphodiesterase-1-inhibitors, could not only attenuate (anti-remodeling) but reverse (reverse-remodeling) the disease. Additionally, new vasodilators, like soluble guanylate cyclase stimulators and activators, addressing well-known and new signaling pathways are currently under investigation. Taken together, with increasing insight into the pathology of PAH, several novel drug targets and treatments have emerged which may improve the management of patients and which efficacy is currently addressed in preclinical studies and clinical trials.

pulmonale arterielle Hypertonie - Gefäßremodeling - Vasokonstriktion

pulmonary arterial hypertension - vascular remodeling - vasoconstriction

Literatur

• 1 Abe K, Shimokawa H, Morikawa K. et al . Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.  Circ Res. 2004;  94 385-393
• 2 Cowan K, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor.  Nat Med. 2000;  6 698-702
• 3 Dumitrascu R, Weissmann N, Ghofrani H A. et al . Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.  Circulation. 2006;  113 286-295
• 4 Ghofrani H A, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension.  N Engl J Med. 2005;  353 1412-1413
• 5 Girgis R E, Mozammel S, Champion H C. et al . Regression of chronic hypoxic pulmonary hypertension by simvastatin.  Am J Physiol Lung Cell Mol Physiol. 2007;  292 L1105-1110
• 6 Guignabert C. et al . Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats.  Circulation. 2005;  111 2812-2819
• 7 Ishikura K, Yamada N, Ito M. et al . Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension.  Circ J. 2006;  70 174-178
• 8 Kao P N. Simvastatin treatment of pulmonary hypertension: an observational case series.   Chest. 2005;  127 1446-1452
• 9 Klein M, Schermuly R T, Ellinghaus P. et al . Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.  Circulation. 2008;  118 2081-2090
• 10 Mittal M, Roth M, König P. et al . Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature.  Circ Res. 2007;  101 258-267
• 11 Murray F, Patel H H, Suda R Y. et al . Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE 1.  Am J Physiol Lung Cell Mol Physiol. 2007;  292 L294-L303
• 12 Patterson K C, Weissmann A, Ahmadi T, Farber H W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.  Ann Intern Med. 2006;  145 152-153
• 13 Rabinovitch M. Elstase and the pathobiology of unexplained pulmonary hypertension.  Chest. 1998;  114 (3 Suppl.) 213S-224S
• 14 Schermuly R T, Dony E, Ghofrani H A. et al . Reversal of experimental pulmonary hypertension by PDGF inhibition.  J Clin Invest. 2005;  115 2811-2821
• 15 Schermuly R T, Pullamsetti S S, Kwapiszeswka G. et al . Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.  Circulation. 2007;  115 2331-2339
• 16 Schermuly R T, Stasch J P, Pullamsetti P A. et al . Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.  Eur Respir J. 2008;  32 881-891
• 17 Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension.  Thorax. 2006;  61 736